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Abstract
The current study was designed to investigate the actions of Anti-Mu ¨llerian Hormone (AMH) on primordial follicle assembly.
Ovarian primordial follicles develop from the breakdown of oocyte nests during fetal development for the human and
immediately after birth in rodents. AMH was found to inhibit primordial follicle assembly and decrease the initial primordial
follicle pool size in a rat ovarian organ culture. The AMH expression was found to be primarily in the stromal tissue of the
ovaries at this period of development, suggesting a stromal-epithelial cell interaction for primordial follicle assembly. AMH
was found to promote alterations in the ovarian transcriptome during primordial follicle assembly with over 200 genes with
altered expression. A gene network was identified suggesting a potential central role for the Fgf2/Nudt6 antisense transcript
in the follicle assembly process. A number of signal transduction pathways are regulated by AMH actions on the ovarian
transcriptome, in particular the transforming growth factor – beta (TGFß) signaling process. AMH is the first hormone/
protein shown to have an inhibitory action on primordial follicle assembly. Due to the critical role of the primordial follicle
pool size for female reproduction, elucidation of factors, such as AMH, that regulate the assembly process will provide
insights into potential therapeutics to manipulate the pool size and female reproduction.
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Introduction
The functional unit within mammalian ovaries is the ovarian
follicle. Each follicle has one oocyte that is surrounded by
granulosa cells and theca cells [1,2]. When ovarian follicles are first
formed, they are formed as primordial follicles. The number of
follicles in the primordial follicle pool is an important determinant
of the reproductive lifespan of a female. Primordial follicles have
an oocyte arrested in the diplotene stage of prophase I of meiosis,
surrounded by flattened pre-granulosa cells [1,2]. These primor-
dial follicles may stay in their arrested state for months, or even
years in long-lived mammals, before undergoing the primordial to
primary follicle transition. Once having undergone follicle
transition, the follicles will either grow and eventually ovulate, or
will undergo apoptosis and follicular atresia [1,3]. Once the pool of
primordial follicles is depleted, reproduction ceases and women
undergo menopause [4,5,6,7].
The formation of primordial follicles is termed follicle assembly.
In embryonic ovaries oogonia proliferate mitotically to form nests
of germ cells that are connected by cytoplasmic bridges [8,9,10].
These germ cell nests become surrounded by epithelial pre-
granulosa cells and have been called ovigerous cords [1,11,12].
The oogonia in germ cell nests enter meiosis to become oocytes
and arrest at diplotene of prophase I [13,14]. During follicle
assembly the germ cell nests break down, and in mice between 1/3
and 2/3 of the oocytes are lost through apoptosis. Pre-granulosa
cells invade to surround individual oocytes and so form primordial
follicles [15,16,17]. In rats follicle assembly occurs starting on the
day of birth and is mostly complete by 5 days of age, although un-
assembled oocytes are sometimes detected at 10 days. In humans
and cattle follicle assembly occurs in mid-gestation [1,18,19,20,
21,22].
There are some extra-cellular signaling molecules that are
known to regulate follicle assembly. Progesterone and estrogen
inhibit follicle assembly [23]. It is thought that changes in the levels
of these hormones in the developing ovary help regulate the timing
of the assembly process [23,24,25,26,27]. Tumor necrosis factor
alpha (TNFa) promotes the oocyte apoptosis that is a part of
follicle assembly [25,28]. Activin is a member of the transforming
growth factor beta family of signaling molecules. Treatment of
mice with Activin-A at the time of follicle assembly results in more
primordial follicles being formed [29]. It has also been shown that
Notch, the receptor for the growth factor Jagged, is present in
oocytes during follicle assembly, and that interfering with Jagged-
Notch signaling inhibits the formation of primordial follicles
[17,30,31]. In the current study, we investigate the role of Anti-
Mu ¨llerian hormone (AMH), also referred to as Mu ¨llerian
Inhibitory Substance (MIS), on the follicle assembly process.
Anti-Mu ¨llerian hormone is a member of the transforming
growth factor beta family of extracellular signaling ligands. AMH
binds to dimeric receptors comprised of the AMH-specific type 2
receptor (AMHR2), and one of three type 1 receptors: BMPR1a
(Alk3), BMPR1b (Alk6) or ACVR1 (Alk2) [32,33]. AMH was
characterized for its role in causing regression of the Mu ¨llerian
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More recently it has been found that Amh is expressed in ovaries
from the granulosa cells of secondary to early antral follicles.
Previous studies have shown AMH acts to inhibit primordial to
primary follicle transition, and so maintains primordial follicles in
their arrested state [36,37,38,39].
Earlier micro-array experiments in our laboratory showed that
Amh mRNA expression levels were altered in the ovaries of new-
born rats, in which oocytes were present in nests, when compared
to four-day old ovaries, in which oocytes were mostly assembled
into primordial follicles [40]. In ovaries of this age there are no
secondary or later stage follicles present from which AMH may be
produced. This opens questions about the source of AMH in these
neonatal ovaries, and what the role of AMH might be during this
time of follicle assembly. In the current study rat ovary organ
culture experiments are used to characterize the actions of AMH
during the time of follicle assembly, when the pool of primor-
dial follicles is formed. The hypothesis tested is that AMH
regulates the rate of assembly of oocytes into primordial follicles.
Immuno-histochemical experiments are performed to determine
the localization of AMH protein expression. Microarray experi-
ments are also performed to determine how gene expression
changes in neonatal ovaries after AMH treatment. Observations
elucidate the regulation of primordial follicle assembly, which is
the process that forms the pool of primordial follicles, and so
ultimately affects the fertile lifespan of women and all other female
mammals.
Results
Whole ovaries from zero-day old rat pups were cultured for
either two or ten days in the presence or absence of AMH. Zero-
day old ovaries after two days of culture have partially completed
the follicle assembly process [23]. Treatments that affect the rate of
follicle assembly may be readily evaluated at this time. At the end
of culture, the ovaries were fixed, sectioned and stained, and then
examined microscopically. The number of oocytes that had been
assembled into follicles was determined, as was the number of
Figure 1. Primordial follicle assembly after 2 days of treatment (A) represented as % Assembled Follicles after AMH, progesterone
(P4) and AMH combined with P4 treatments. Oocyte number per cross section (B) after the same treatments. The Mean 6SEM from a minimum
of five different experiments performed in replicate with statistical significance indicated as (**) (P,0.01).
doi:10.1371/journal.pone.0020087.g001
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two days were treated with AMH (50 ng/mL), progesterone
(P4)(10
26 M), or the combination of AMH and P4. Progesterone
has previously been shown to slow the rate of follicle assembly
[23], and was used as a positive control in these experiments.
Treatment with AMH resulted in a significant (p,0.01) decrease
in the percentage of assembled follicles compared to untreated
controls (Figure 1A). Treatment with P4, as expected, resulted in a
significant (p,0.01) decrease in assembled follicles. The combi-
nation of AMH and P4 also resulted in a significant (p,0.001)
decrease in assembled follicles compared to controls (Figure 1A). A
corresponding increase in oocyte number compared to controls
was observed in the AMH treated ovary cultures (Figure 1B),
suggesting the apoptosis of oocytes was inhibited resulting in an
increase in oocyte number. AMH-induced alterations in oocyte
apoptosis may be an aspect of the mechanism in the inhibition of
follicle assembly. These results indicate that AMH can slow the
rate of follicle assembly.
Rat ovaries were cultured for ten days to determine if AMH
treatment could have an effect on the size of the assembled
primordial follicle pool. Ovaries cultured for ten days, similarly to
those treated for two days, were treated with AMH (50 ng/mL),
P4 (10
26 M), or the combination of AMH and P4. Results indicate
none of the treatments affected oocyte number after 10 days of
treatment (Figure 2B). Therefore, the alterations in primor-
dial follicle assembly regarding primordial follicle pool size
was corrected after 10 days of culture. Similarly, there was no
difference in the percentage of assembled follicles between
treatments after 10 days (Figure 2A). Ovaries cultured for 10
days appeared healthy with minimal necrosis of follicular cells.
Un-assembled oocytes were present in small nests of 2–3 oocytes
(Figure 2C and 2D).
Figure 2. Primordial follicle pool size and percentage of assembled follicles as determined by oocyte counts per cross section after
10 days of treatment with AMH, progesterone (P4) and AMH combined with P4. The mean 6SEM for a minimum of three experiments in
replicate performed. (A) Percent assembled follicles. (B) Total oocytes per cross-section. (C) Representative untreated control ovary section, H&E
stained. (D) Representative AMH treated ovary section, H&E stained.
doi:10.1371/journal.pone.0020087.g002
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AMH protein was localized in neonatal rat ovaries (Figure 3).
Confocal fluorescent microscopy showed that AMH was localized
to stromal cells surrounding oocyte nests and primordial follicles
(Figure 3A and 3C). AMH protein did not appear to be present in
oocytes. Examining the pattern of AMH expression across an
ovary cross-section reveals that there is a region of high expression
levels near the ovarian cortex around forming follicles, and also
expression in selected bands of stromal tissue in the interior of the
ovary (Figure 3E). The stromal localization of AMH at this period
of ovarian development suggests an important stromal-epithelial
interaction in follicle assembly.
RNA was collected from rat ovaries that had been placed into
culture at zero days of age and cultured with or without AMH
treatment for one day. A 24-hour treatment was not found to
effect any morphology or follicle development (data not shown),
such that any effects in the transcriptome are not due to
differential morphogenesis of the ovary. The RNA from each
treatment group was subjected to microarray analysis using
Affymetrix Rat Gene 1.0 ST chips. The microarray data for the
different arrays were found to match very well after processing of
the data (Figure S1). Compared to controls, AMH treated ovary
RNA showed changes in the expression of 285 probe sets,
mapping to 274 different genes (Figure S2). This list of altered
genes (Table S1) was analyzed using several different methods to
gain insights into the functional processes impacted by AMH
signaling. The genes were categorized into functional categories
that demonstrated metabolism, signaling and transcription func-
tions were the most highly represented, Figure 4 and Table S2.
The majority of genes were up-regulated (189) with a smaller
number down-regulated (85), Figure 4. The list of differentially
expressed genes was also analyzed to see what well-characterized
cellular signaling pathways these genes fell into using KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway analysis.
The altered genes were found to associate with several signaling
pathways (Table 1). The most highly represented pathway with the
highest impact was the TGFß signaling pathway, Figure 5. The
expression of a number of critical TGFß signal transduction genes
were modified. Other signaling pathways effected were calcium
signaling and cell adhesion molecule signaling among the KEGG
pathways impacted by these genes (Table 1). An automated
analysis of the 274 differentially expressed genes (Pathway Studio,
Ariadne, Inc.) revealed that a subset of these genes were associated
with a gene network. A sub-network formed from these related
and connected genes is presented in Figure 6 that demonstrates a
potential central role for the Nudt6 antisense gene for the fibroblast
growth factor-2 gene (Fgf2). The cellular processes that this
signaling event regulates had a high degree of connectivity with the
AMH altered genes (Table S2). This gene network will be
important to consider in regulating primordial follicle assembly. A
more global view of signaling events influenced by AMH are
presented in Figure S3. A number of different signaling pathways
appear to be altered by AMH actions on primordial follicle
assembly, Table 1 and Figure S3.
Discussion
Previous investigations demonstrated that AMH was expressed
in the ovaries of new-born rats and the level of Amh mRNA
expression was different in zero-day old ovaries containing oocyte
nests when compared to four-day old ovaries having mostly
assembled primordial follicles [40]. The current studies were
designated to determine what role anti-Mu ¨llerian hormone (AMH)
has in regulating the formation of primordial follicles. Organ
culture experiments were performed in which neonatal rat ovaries
were treated with AMH during the time of follicle assembly. Both
zero-day old rat ovaries cultured for two days and in vivo ovaries
from two-day-old rats have partially completed the follicle
assembly process [1,2,3,23]. Experimental treatments either in
vitro or in vivo that affect the rate of follicle assembly may be readily
evaluated at this time point. In vivo the follicle assembly process is
essentially completed by 4–5 days of age. However, when zero-
day-old rat ovaries are cultured for 4 to 6 days, a larger portion of
oocytes remain un-assembled in nests compared to what is seen in
vivo [23]. Even after ten days of culture, small oocyte nests are
retained, both in the current study and in previous research [41].
So evaluations of follicle pool size are performed after ten days of
culture, when oocyte loss is expected to have stabilized.
AMH treatment for two days inhibited primordial follicle
assembly (Figure 1). The affect of AMH was similar to that of
progesterone, a previously identified inhibitor of follicle assembly
in rats and cattle [23,24,26]. A corresponding increase in oocyte
number was associated with the inhibition of follicle assembly. The
majority of oocytes undergo apoptosis during follicle assembly, so
Figure 3. Ovarian morphology and immunohistochemical
localization of AMH. (A) Fluorescent immunohistochemical localiza-
tion of AMH protein (green) in cortex of 3-day old rat ovary.
(B) Hematoxylin/eosin (H and E) stain of the same ovarian section as
was used for immunohistochemistry. (C) Overlay of immunohistochem-
ical localization of AMH (green) onto H and E stained section (i.e. A onto
B). AMH is present in the stromal cells around groups of forming and
newly formed primordial follicles. (D) An additional H and E stained
ovarian cross-section from the same ovary, with more clear morpho-
logical detail than was possible with the re-stained section in B.
(E) Immunohistochemical localization of AMH across the entire ovarian
cross-section, showing AMH to be present near the ovarian cortex and
in stromal bands in tzhe medulla.
doi:10.1371/journal.pone.0020087.g003
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These results indicate that AMH acts to inhibit the rate of
primordial follicle formation. This is one of the first growth factors
shown to inhibit primordial follicle assembly. After ten days of
culture only small oocyte nests are present [41], and no difference
in the primordial follicle pool was observed. The cultured ovaries
appeared morphologically healthy. Therefore, alterations during
primordial follicle assembly were corrected after ten days of
ovarian culture. The actions of AMH appear to be focused on the
initial stages of primordial follicle assembly.
Immunohistochemical studies showed that AMH protein was
localized to the ovarian stromal cells surrounding germ cell nests
and newly formed primordial follicles (Figure 3). These stromal
cells appear to be the source of the AMH that acts to inhibit follicle
assembly. This is different than what is seen in the ovaries of older
animals. In ovaries from adult animals AMH acts to inhibit the
transition of arrested primordial follicles to developing primary
follicles [42]. In these adult ovaries AMH is produced from the
granulosa cells of developing follicles from the late secondary to
early antral stages [36,37,38,39]. Granulosa cells are an epithelial
cell type, and so are distinct from the stromal cells where AMH is
localized in the younger animals of the current study. Observa-
tions suggest an important stromal-epithelial cell interaction
during primordial follicle assembly. Mutant mice mull for the
AMH gene can still successfully form primordial follicles [38], so
AMH signaling may modulate the timing of initiation of follicle
assembly, and likely acts in concert with other regulatory growth
factors. Even though the sites of AMH localization are different, it
is interesting that the role of AMH in both neonatal and
adult ovaries is to inhibit the progression of primordial follicle
development. A recent study [43] reported AMH expression in
developing primary follicles of 4-day old rat ovaries, rather than in
surrounding stroma. In the 3-day old ovaries evaluated in the
current study, follicle assembly was not complete, and no
developing primary follicles were apparent. This raises the
possibility that there is a switch in AMH expression from stromal
to epithelial cell types at the completion of follicle assembly.
The mRNA from 0-day old ovaries treated with AMH was
compared with that of untreated controls using a microarray
analysis. It was found that transcripts from 274 genes were
differentially expressed in AMH-treated ovaries. Genes from this
list are known to be involved in processes of cell signaling,
differentiation, proliferation and apoptosis, as might be expected
in ovaries undergoing assembly of primordial follicles. AMH is a
member of the TGFß family of growth factors. Several of the
differentially expressed genes known to be involved in TGFß
family signaling pathways including Smad6, Smad7, Smad9, Tgfbr3
(betaglycan) and the additional signaling ligand gene Bmp3 (bone
morphogenetic protein 3) were found to be regulated by AMH
(Figure 5). This further indicates that TGFß family signaling is
important to the follicle assembly process. BMP growth factors
have previously been shown to be expressed in adult rat ovaries in
theca cells of antral follicles [44] and influence primordial follicle
development [45]. The TGFß growth factor can inhibit cell
proliferation, inhibit apoptosis and promote cell survival [46].
TGFß can promote the cell cycle inhibitor p27 to arrest the cell
cycle G1 phase [47], directly inhibit the apoptosis signaling
pathway [47], and promote extracellular matrix production and
Figure 4. Number of genes differentially expressed in rat P0-ovary upon AMH treatment and their distribution among main
functional categories. Dark-grey - up-regulated (189 genes) and light-grey - down-regulated genes (85 genes).
doi:10.1371/journal.pone.0020087.g004
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signal transduction pathway, Figure 5, during primordial follicle
assembly blocks oocyte apoptosis to inhibit follicle assembly.
Observations suggest this may be the primary mechanism for
AMH actions.
A number of genes for additional growth factors and extra-
cellular signaling ligands were also differentially expressed in
AMH-treated ovaries (Table S1). Cx3cl1 has been shown to have a
role in adult ovary progesterone synthesis [49], but its role in
primordial follicle development has not been investigated.
Similarly, Rspo1 is known to have a role in embryonic ovarian
differentiation [50,51,52], but its role in later stages of ovarian
development have not been examined. Other signaling ligands
such as Creg1, Ecop and Megf6 were not previously known to be
expressed in ovaries. Further research is needed to determine if
any of these genes are involved in primordial follicle assembly. As
previously suggested [1], a network of growth factor mediated
interactions will likely be required to regulate primordial follicle
development.
A gene network was identified of the most interactive and
connected genes within the AMH differentially regulated genes,
Figure 6. The genes Bmp3 and the Smad transcription factors were
present, further confirming the role of this pathway in the actions
of AMH on follicle assembly. A central regulatory factor in the
gene network identified is the Nudt6 antisense transcript for the
fibroblast growth factor 2 gene (Fgf2) expression product. The
Nudt6 is an embedded reverse transcript within the Fgf2 gene
[53,54] that has the capacity to inhibit the expression and action of
FGF2 [55,56]. This FGF2/NUDT6 relationship indicates a
critical regulatory role in the gene network identified, Figure 6,
to influence signal transduction processes and transcriptional
regulation. The observations of the current study suggest these
genes and the network identified are potential candidates involved
in the regulation of primordial follicle assembly. Future research
on the role of these genes and this network is anticipated to help
elucidate the molecular regulation of primordial follicle assembly.
A recent study demonstrated that a bionetwork of interacting
genes was important for regulating the transition of arrested
primordial follicles into developing primary follicles [57]. An
important finding from that study was that several growth factors
that affected follicle transition also impacted many of the same
signaling pathways, but that each different growth factor affected
different geneswithinthosepathways. In the currentstudyit maybe
that AMH affects expression of a different set of genes than other
factors impacting follicle assembly, but that other regulatory factors
effect similar pathways.Studies areinprogress to test this hypothesis
with a bionetwork analysis of primordial follicle assembly.
The primordial follicle pool size and development helps
determine the reproductive capacity of most mammalian species.
Abnormal primordial follicle development is associated with
premature ovarian failure and menopausal conditions [1]. The
factorsthat controlthe assemblyof primordial follicles have a role in
establishing the follicle pool size and so indirectly the reproductive
capacity of a female. The current study has identified AMH as an
important regulator of primordial follicle assembly that appears to
mediate a stromal-epithelial interaction in the developing ovary to
inhibit follicle assembly. Perhaps AMH from stromal cells has an
important role in maintaining the oocyte nests to prevent premature
follicle assembly. The balance of inhibitory signals such as AMH
and progesterone with growth factors that promote follicle assembly
such as TNFa, activin and jagged will determine whether follicle
assembly will proceed. In the current study a gene network
potentially involved in primordial follicle assembly was identified
and may be used to design therapeutic agents to manipulate the
primordial follicle pool size. Potential additional regulatory agents
for follicle assembly were also identified.
Methods
Treatments and ovary culture
Zero-day old female Sprague-Dawley rats (Harlan Laboratories,
Inc., USA) were euthanized according to Washington State
University IACUC approved protocols and their ovaries removed
and cultured whole as described previously [58]. All procedures
were approved by the Washington State University Animal Use
and Care Committee (IACUC approval # 02568-018). Zero-day
Table 1. Top KEGG signaling pathways enriched with genes differentially expressed in P0 ovary upon AMH treatment (274 genes).
Pathway Name Impact Factor
Differentially Regulated
Genes in Pathway Total Genes in Pathway
TGF-beta signaling pathway 9.35 5 81
Calcium signaling pathway 5.87 4 189
General signaling pathways (Pathways in cancer) 5.19 6 321
Melanogenesis 4.61 3 96
Cell adhesion molecules (CAMs) 4.29 5 151
Regulation of actin cytoskeleton 4.02 4 204
Cell cycle 3.10 3 117
Neuroactive ligand-receptor interaction 2.48 5 259
ECM-receptor interaction 2.42 3 74
Axon guidance 2.27 3 124
Endocytosis * 4 226
Glycerophospholipid metabolism * 3 76
Arrhythmogenic right ventricular cardiomyopathy (ARVC) * 3 71
Malaria * 3 56
Asterisks (*) indicates a pathway not in ONTO-tools database (see Methods), so, impact factors for them have not been calculated.
doi:10.1371/journal.pone.0020087.t001
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oocytes. Whole ovaries were cultured on floating filters (0.4 mm
Millicell-CM, Millipore, Bedford, MD, USA) in 0.5 ml Dulbec-
co’s modified Eagle’s medium (DMEM)-Ham’s F-12 medium
(1:1, vol/vol) containing 0.1% BSA (Sigma), 0.1% Albumax
(Gibco BRL, Gaithersburg, MD, USA), 27.5 mg/ml transferrin,
and 0.05 mg/ml L-ascorbic acid (Sigma) in a four-well culture
plate (Nunc plate, Applied Scientific, South San Francisco, CA,
USA) for two or ten days. Previous studies have shown that zero-
day-old ovaries cultured for ten days have good cell viability [41].
The medium was supplemented with penicillin and streptomycin
to prevent bacterial contamination. Ovaries were randomly
assigned to treatment groups, with 1–3 ovaries per floating filter
per well. Wells were treated every two days with recombinant
AMH (human Anti-Mu ¨llerian Hormone)(50 ng/mL, R&D
Systems Inc., USA) and/or progesterone (P4) (Sigma) at
10
26 M. Pilot studies in our laboratory indicated that 50 ng/mL
AMH had a maximal effect on primordial to primary follicle
transition in cultured neonatal rat ovaries (data not shown). After
culture, ovaries were fixed in Bouin’s fixative (Sigma) for two
hours. Ovaries were then embedded in paraffin, sectioned at
3 mm and stained with hematoxylin/eosin for use in morpho-
logical analysis.
Morphological Analysis
For each ovary the number of oocytes at each developmental
stage was counted and the counts for each stage were averaged
across the two consecutive histological sections that had the largest
ovarian cross section. The oocyte nucleus had to be visible for an
oocyte to be counted. Normally, between 100 and 300 follicles
were present in each cross-section. Oocytes were classified as being
not yet assembled into follicles (i.e. the oocyte was part of an
unassembled oocyte nest), as primordial (stage 0) or as one of the
developing pre-antral stages (stages 1–4) as described previously
[23,59]. Unassembled oocytes are recognized from their being
grouped together without any intervening stromal cells. Primordial
follicles consist of an oocyte partially or completely surrounded by
a single layer of squamous pre-granulosa cells. Follicles with only
one cuboidal granulosa cell visible, the rest being squamous, were
also classified as primordial [60,61,62,63]. Developing (stages 1–4)
follicles contain successively more cuboidal granulosa cells in layers
around the oocyte [59,64].
Figure 5. TGF-beta Signaling Pathway (KEGG) showing rat P0-Ovary genes affected by AMH treatment. Red boxes – up-regulated,
green and white boxes –not affected genes.
doi:10.1371/journal.pone.0020087.g005
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Ovary sections from 3-day old un-cultured rat ovaries were
immunostained as described previously [65], for the presence of
AMH using an anti-AMH primary antibody (anti-AMH goat IgG;
R&D Systems, USA). Briefly, 3 mm sections were de-paraffinized,
rehydrated through a graded ethanol series, boiled in 10 mM
sodium citrate buffer, washed with 0.1%Triton-X solution, and
then blocked with 10% goat serum (normal goat serum; Vector
Laboratories Inc., Burlingame, CA, USA) for 20 min prior to
incubation with 5 mg/ml primary antibody for 12 h. The sections
were then washed with PBS and incubated with 1:3000 diluted
conjugated secondary antibodies for 45 min (Alexafluor donkey
anti-goat IgG and Alexafluor donkey anti-mouse IgG; Invitrogen),
and then again washed several times before mounting with
cover slips. Images were captured using a con-focal fluorescent
microscope (Zeiss 510). Positive control sections of testes showed
the expected staining of Sertoli cells (data not shown), confirming
the specificity of the anti-AMH antibody. Negative control
experiments were performed using non-specific primary antibody
at 5 mg/ml (goat IgG; R&D Systems).
RNA Collection
For ovary culture experiments in which ovarian RNA was
collected, 2–3 ovaries per well were cultured for one day either
untreated (controls) or were treated with AMH (human Anti-
Mu ¨llerian Hormone) (50 ng/mL, R&D Systems Inc., USA). After
one day of culture there are no morphological differences
between control and growth factor-treated ovaries (data not
shown), so measurements of whole-ovary gene expression will
reflect differences in RNA transcription, rather than differing
Figure 6. Gene network with direct connection scheme for AMH treated P0-ovary differentially expressed genes. Only 31 genes
directly connected from the list of 274 are shown according to their location in the cell (on membrane, in Golgi apparatus, nucleus, cytoplasm or
outside the cell), the rest of genes are not connected and not shown. Node shapes code: oval and circle – protein; diamond – ligand; circle/oval on
tripod platform – transcription factor; ice cream cone – receptor. Red color represents up-regulated genes, blue color – down-regulated genes; arrows
with plus sign show positive regulation/activation, arrows with minus sign – negative regulation/inhibition; grey arrows represent regulation, lilac -
expression, and purple – binding.
doi:10.1371/journal.pone.0020087.g006
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between treatments.
RNA was isolated from whole rat ovaries after homogenization
in one mL Trizol
TM reagent (Sigma-Aldrich, USA), according to
manufacturer’s instructions. 2–3 ovaries from the same culture
well (from different rat pups out of the same litter) and receiving
the same treatment were pooled and homogenized together.
Homogenized samples were stored at 270C until the time of RNA
isolation.
Microarray transcriptome analysis
The mRNA processing and hybridization were performed at
the Genomics Core Laboratory, Center for Reproductive Biology,
Washington State University, Pullman, WA using standard
Affymetrix reagents and protocol. Briefly, mRNA was transcribed
into cDNA with random primers, from the later, cRNA was
transcribed, and from that, single-stranded sense DNA was
synthesized which was fragmented and labeled with biotin.
Biotin-labeled fragmented ssDNA was then hybridized to the
Rat Gene 1.0 ST microarrays containing more than 27,000
transcripts (Affymetrix, Santa Clara, CA, USA). Hybridized chips
were scanned on Affymetrix Scanner 3000. CEL files containing
raw data were then pre-processed and analyzed with Partek
Genomic Suite 6.5 beta software (Partek Incorporated, St. Louis,
MO) using an RMA and GC-content adjusted algorithm. The
signals from an average of 28 different probes for each transcript
were compared to give a single value. Lists of differentially
expressed genes for each treatment were generated using following
cut off criteria: signal ratio Control/Treatment .1.20 change,
mean difference for un-logged signals between control and
treatment .10, t-test p-values,0.05, and correcting for organ
culture date batch effects.
CEL files (MIAME compliant raw data) from this study have
been deposited with the NCBI gene expression and hybridization
array data repository (GEO, http://www.ncbi.nlm.nih.gov/geo,
#GSE 25629) and can be also accessed through www.skinner.wsu.
edu. For gene annotation, Affymetrix annotation file RaGen-
e1_0stv1.na31.rn4.transcript.csv was used unless otherwise spec-
ified. Generation of affected KEGG pathways (Kyoto Encyclope-
dia for Genes and Genome, Kyoto University, Japan) used
Pathway-Express, a web-based tool freely available as part of the
Onto-Tools (http://vortex.cs.wayne.edu) [66].
Previous studies have demonstrated that microarray data are
validated with quantitative PCR data [40,67]. Due to the presence
of an average of 28 different oligonucleotide probes for each
specific gene being used on the microarray versus only a single
primer set for a gene in a quantitative PCR, the microarray is
more effective at eliminating false positive or negative data and
provides a more robust quantification of changes in gene
expression.
Statistical Analysis
Treatment groups are compared using analysis of variance
(ANOVA) followed by Dunnet’s post-hoc tests where appropriate.
Groups were considered statistically significant with P#0.05. All
statistics were calculated using Graph Pad Prism version 5.0b for
Macintosh, Graph Pad Software, San Diego, CA, USA.
Supporting Information
Figure S1 Sample histograms and box plots for micro-
array raw data (A) and pre-processed signal values,
using RMA, GC-content adjusted algorithm (B) for
control (blue) and 3 AMH treated (red) chips.
(PDF)
Figure S2 Heatmap for AMH-treated P0-ovary 274
differentially expressed genes obtained with Partek GS
6.5 software. Means for control and AMH samples are shown:
highly expressed genes colored in red, low expressed in green,
medium expressed in yellow.
(PDF)
Figure S3 General Signaling Pathways showing rat P0-
ovary genes affected by AMH treatment: red boxes – up
regulated, blue – down-regulated, green and white boxes
– not affected genes.
(PDF)
Table S1 Genes expressed differen6ally in P0 Ovaries
upon an6-Mullerian (AMH) hormone treatment.
(PDF)
Table S2 Top cell processes for 274 differentially
expressed genes in AMH-treated P0-ovary. Cell processes
with highest local connectivity values (number of related literature
references) were extracted from shortest connection subnetwork
obtained with Pathway Studio 7.0 software (Ariadne Genomics,
Inc., Rockville, MD).
(PDF)
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